Fig. 3

Fig. 3

Fig. 3. Vegfr tyrosine kinase inhibitors, DMH4 and AV-951, block CNS angiogenesis but not barriergenesis. (A) Representative confocal images (dorsal views; anterior left) of untreated, DMSO-treated, or inhibitor-treated glut1b:mCherry, plvap:EGFP embryos. Embryos were treated at 24 hpf then imaged at 54 hpf. Note that the inhibitor-treated embryos lack CtAs but express glut1b:mCherry in the PHBCs indicating that barriergenesis occurs in the absence of CNS angiogenesis. In addition, 1 ​μM DMH4 was as effective as 5 ​μM DMH4 at blocking CNS angiogenesis. AV-951 (1 ​μM) showed similar effects as 5 ​μM DMH4. Scale bars are 100 ​μm (top left) and 50 ​μm (top right). (B) Quantification of the number of CtAs at 2 dpf for untreated, DMSO-treated, or inhibitor-treated embryos (n ​= ​3). (C) Quantification of the normalized RFI of glut1b:mCherry in untreated, DMSO-treated, or inhibitor-treated embryos at 2 dpf (n ​= ​3). Data for (B) and (C) are presented as means ​± ​SEM (∗∗∗p ​< ​0.001; ns ​= ​not significant).